centers of excellence for the treatment of cancer. The �ght against cancer is to a signi�cant extent a question of managing knowledge acquired very quickly. Investment will be made in training and research on the federal level.» To conclude the political part, Peter Brauchli, CEO of Oncosuisse, explained the implementation of the project ‚strategy against cancer‘, pointing out the short time frame and the ambitious outcome of involving all actors in the scienti�c and the political �eld. In his �nal statement Richard Herrmann, president of Oncosuisse, expressed the wish that the cooperation and mutual understanding of political leaders on the one hand and cancer organizations on the other will allow to face the capacious task of the coming year. He expressed his wish, to present the �rst results of the strategy in the next cancer reporting day in 2013. See also program and presentations of the event: www.oncosuisse.ch Contact Marcel Wyler, National Cancer Program 2011–2015 marcel.wyler@oncosuisse.ch PUBLICATIONS Lymphoma Renner C, Zinzani P, Gressin R, Klingbiel D, Dietrich PY, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N. A multicenter phase II trial (SAKK 36/06) of singleagent Everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. <strong>2012</strong> Feb 7 von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-Intensi�cation in Early Unfavorable Hodgkin’s Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol. <strong>2012</strong> Jan 23 Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identi�es a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol. <strong>2012</strong> Jan 15 SAKK Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Maschmeyer G, Helke K, Kessler C, Niederwieser D, Busemann C, Schroeder H, Vogelgesang S, Kirsch M, Montemurro M, Krüger WH, Dölken G; for the Ostdeutsche Studiengruppe Hämatologie und Onkologie. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and responseadapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann Oncol. 2011 Nov 24 Lung Cancer Antonio Rossi, Massimo Di Maio, Paolo Chiodini, Robin Michael Rudd, Hiroaki Okamoto, Dimosthenis Vasilios Skarlos, Martin Früh, Wendi Qian, Tomohide Tamura, Epaminondas Samantas, Taro Shibata, Francesco Perrone, Ciro Gallo, Cesare Gridelli, Olga Martelli, and Siow- Ming Lee. Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. JCO. <strong>2012</strong> April 2 Gastrointestinal Cancer Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, Van Cutsem E, Xie T, Bosman FT, Roth AD, Delorenzi M. Identi�cation of a Poor-Prognosis BRAFMutant-Like Population of Patients With Colon Cancer (SAKK60/00). J Clin Oncol. <strong>2012</strong> Mar 5. SAKK Dates <strong>2012</strong> – August 28 Training Course for CRC’s and CTN’s – September 4 Board Meeting – October 18 & 25 SAKK Investigators’ Education – October 25 & 26 Board Retraite – November 1 State of the Art in Oncology Research – November 21 General Assembly – November 22 & 23 Semi-Annual Meeting Correspondence: Annik Steiner Swiss Group for Clinical Cancer Research Communications Ef�ngerstrasse 40 CH-3008 Bern annik.steiner@sakk.ch Schweizer Krebsbulletin � Nr. 2/<strong>2012</strong> 135
The Gateway for Cancer Research (Gateway), a U.S.-based non-profit organization, and the Swiss Group for Clinical Cancer Research (SAKK) have joined forces for this unique opportunity. We call upon all investigators to submit clinical research proposals for innovative, patient-centered phase II clinical cancer trials aimed at finding new therapeutic approaches to help cancer patients feel better, live longer or be cured TODAY! Depending on the nature of the project, the grant is endowed for a maximum of up to US$ 450,000. Application deadline is November 30, <strong>2012</strong>. Research proposals must be submitted in Word format with an abbreviated CV. Please include any published work in the research proposal. The winning proposal will be announced in the 2 nd quarter of 2013. Investigators should contact The Gateway for Cancer Research (www.demandcurestoday.org) or SAKK (www.sakk.ch) for application information. Eveline Mumenthaler Prof. Dr. Beat Thürlimann Director of Research & Grants President SAKK The Gateway for Cancer Research Email: sakkcc@sakk.ch Email: eveline.mumenthaler@gatewaycr.org 136 Schweizer Krebsbulletin � Nr. 2/<strong>2012</strong>